{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:53Z","timestamp":1786118993472,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/nan.0b013e31819228ee","type":"journal-article","created":{"date-parts":[[2009,1,13]],"date-time":"2009-01-13T03:13:12Z","timestamp":1231816392000},"page":"45-52","source":"Crossref","is-referenced-by-count":5,"title":["Enzyme Replacement Therapy in the Home Setting for Mucopolysaccharidosis VI"],"prefix":"10.1097","volume":"32","author":[{"given":"Cynthia","family":"Tifft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Proud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"DeMarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Nicely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Turbeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"4","key":"R1-8-20210208","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/humu.1190","article-title":"Mucopolysaccharidosis type VI: structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase.","volume":"18","author":"Litjens","year":"2001","journal-title":"Hum Mutat"},{"key":"R4-8-20210208","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).","volume":"144","author":"Harmatz","year":"2004","journal-title":"J Pediatr"},{"issue":"6","key":"R5-8-20210208","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","article-title":"Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetlygalactosamine-4-sulfatase.","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"R6-8-20210208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled multinational study of recombinant human N-acetylgalactosamine-4-sulfatase (rhASB) and follow-on open-label extension study.","volume":"148","author":"Harmatz","year":"2006","journal-title":"J Pediatr"},{"issue":"6","key":"R7-8-20210208","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10545-007-0686-8","article-title":"Home treatment with enzyme replacement therapy for mucopolysaccharidosis type 1 is feasible and safe.","volume":"30","author":"Cox-Brinkman","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"R8-8-20210208","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI.","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"R9-8-20210208","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0002-8703(98)70352-7","article-title":"Beneficial effects of intermittent home administration of the inotrope\/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study.","volume":"135","author":"Cesario","year":"1998","journal-title":"Am Heart J"},{"key":"R10-8-20210208","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zolendronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised crossover study of community versus hospital bisphosphonate administration.","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"}],"container-title":["Journal of Infusion Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00129804-200901000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:30:31Z","timestamp":1786037431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00129804-200901000-00008"}},"subtitle":["A Survey of Patient Characteristics and Physicians' Early Findings in the United States"],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/nan.0b013e31819228ee","relation":{},"ISSN":["1533-1458"],"issn-type":[{"value":"1533-1458","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}